MedTrace Logo

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

NCT04684485 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-12-30

Study results available
· View outcomes & findings →

Summary

This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.

Conditions

  • Dermatitis, Atopic

Interventions

DRUG

Placebo

Placebo Tablet of SCD-044 product in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 1

SCD-044 tablets of low dose (Dose 1) in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 2

SCD-044 tablets of intermediate dose (Dose 2) in subjects with moderate to severe atopic dermatitis.

DRUG

SCD-044_Dose 3

SCD-044 tablets of high dose (Dose 3) in subjects with moderate to severe atopic dermatitis.

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-30
Primary Completion
2024-11-11
Completion
2025-03-18
FDA Drug
Yes

Countries

  • United States
  • El Salvador
  • Estonia
  • Georgia
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04684485 on ClinicalTrials.gov